United States Endometriosis Treatment Market Size, Share, Growth, and Industry Analysis, By Drug Type (Hormonal TherapyGonadotropin-Releasing Hormone (GnRH) Agonists Oral Contraceptives Progestins Danazol , Non-Hormonal Therapy NSAIDs Analgesics ), By Route of Administration (Oral , Injectables, Nasal , Others (e.g., implants, transdermal patches) ) and Forecast, 2026-2034

United States Endometriosis Treatment Market Trends

Shift Toward Convenient Long-Duration and Investigational Therapies

Treatment is shifting toward convenient oral regimens and longer-term medical management. MYFEMBREE is a once-daily oral therapy approved for moderate-to-severe endometriosis pain for up to 24 months. Its pivotal SPIRIT program involved more than 1,200 women across two 24-week studies; 75% of treated participants achieved clinically meaningful dysmenorrhea reduction compared with 27% and 30% in placebo groups. These outcomes support movement toward therapies capable of reducing dependence on repeated invasive intervention.

Pipeline diversification is simultaneously increasing. The NOVA Phase 2 study of vipoglanstat targets enrollment of 190 patients and evaluates 2 doses, with estimated completion in June 2027. A separate pivotal at-home stimulation study enrolled an estimated 120 participants and was scheduled for completion in August 2026. These programs illustrate technology shifts spanning pharmacological and device-based treatment rather than reliance on a single therapeutic mechanism.

United States Endometriosis Treatment Market Drivers

High Disease Burden and Expanding Long-Term Treatment Requirements

High prevalence creates a substantial addressable treatment population. More than 11% of U.S. women aged 15–44, exceeding 6.5 million individuals, are estimated to have endometriosis. Industry reporting has also cited approximately 7.5 million U.S. premenopausal women affected and diagnostic delays ranging from 4 to 11 years. Combined with chronic pain, fertility concerns, and recurrence, this burden encourages greater diagnosis, sustained pharmaceutical management, specialist referral, and adoption of therapies designed for periods extending to 24 months.

United States Endometriosis Treatment Market Restraints

Safety Monitoring and Persistent Diagnostic Delays

Treatment duration and tolerability remain constraints. MYFEMBREE carries a treatment-duration limit of up to 24 months, while clinical evidence reported mean bone-mineral-density changes below 1% through 1 year; 19.7% of extension-study patients experienced losses above 3%. At the patient pathway level, diagnosis may require 4–11 years, creating a prolonged period before targeted therapy begins. These factors can limit persistence, increase monitoring requirements, and sustain demand for safer long-duration alternatives.

United States Endometriosis Treatment Market Opportunities

Expansion of Non-Hormonal and Multimodal Treatment Pipelines

Innovation beyond conventional hormone suppression creates an important opportunity. The 190-patient Phase 2 NOVA trial evaluates 2 doses of vipoglanstat against placebo and has an estimated June 2027 completion. Meanwhile, a randomized U.S. study updated in June 2026 continues evaluating medical management following excisional surgery, indicating ongoing interest in combining surgical and pharmaceutical approaches. Such programs could broaden options for patients unable or unwilling to remain on hormonal regimens.

Challenges in United States Endometriosis Treatment Market

Heterogeneous Symptoms Complicate Treatment Selection

Endometriosis presents with painful periods, fatigue, lower abdominal or back pain, heavy bleeding, and painful intercourse, while treatment can span OTC analgesics, prescription medicines, oral contraceptives, GnRH therapies, cyst removal, adhesiolysis, and hysterectomy. Clinical heterogeneity complicates standardized pathways: SPIRIT studies enrolled more than 1,200 women, yet dysmenorrhea response reached 75% while non-menstrual pelvic-pain response ranged from 59% to 66%, demonstrating that therapeutic outcomes differ by symptom endpoint.

United States Endometriosis Treatment Market Segmentation

The market is segmented by drug type, route of administration, surgery type, distribution channel, and end-user. Drug-type revenue indicates hormonal therapy held approximately 64.42% in 2026, while oral products represented about 44.62% of route-based revenue. The supplied dataset provides quantitative forecasts only for drug type and administration route; surgery, channel, and end-user figures are therefore not fabricated.

By Drug Type

Hormonal therapy is the largest drug category, rising from USD 323.83 million in 2025 to USD 365.80 million in 2026 and USD 969.70 million by 2034 at a 12.96% CAGR. It includes GnRH agonists, oral contraceptives, progestins, and danazol and accounts for approximately 64.42% of 2026 drug-type revenue.

Non-hormonal therapy, including NSAIDs and analgesics, increases from USD 178.47 million in 2025 to USD 202.06 million in 2026 and USD 545.60 million by 2034. At 13.22%, it is the faster-growing drug category, exceeding hormonal therapy's 12.96% CAGR by 0.26 percentage points.

By Route of Administration

Oral administration is the largest route, advancing from USD 224.18 million in 2025 to USD 253.37 million in 2026 and USD 674.52 million in 2034 at a 13.02% CAGR. It represents approximately 44.62% of 2026 route-based revenue, compared with roughly 25.00% for injectables and 15.30% for nasal products.

Other administration routes, including implants and transdermal patches, are fastest-growing at a 13.66% CAGR, increasing from USD 75.35 million in 2025 to USD 85.64 million in 2026 and USD 238.54 million in 2034. Injectables reach USD 376.35 million at 12.96%, while nasal therapies reach USD 226.50 million at 12.72%.

By Surgery Type

Surgery is divided into conservative procedures laparoscopy and laparotomy and definitive surgery, principally hysterectomy with or without oophorectomy. The supplied tables assign USD 0 in separately reported surgical revenue because no surgery-specific numerical dataset was provided; accordingly, no unsupported 2026 share or 2026–2034 CAGR is introduced.

The same limitation applies to identifying a numerical fastest-growing surgical subsegment. Surgical care nevertheless remains part of the treatment continuum alongside pharmaceutical management, with the available clinical literature recognizing adhesiolysis, cyst removal, and hysterectomy among treatment options.

By Distribution Channel

Distribution includes hospital pharmacies, retail pharmacies, and online pharmacies. The mandatory dataset provides USD 567.86 million in total 2026 drug-type revenue and USD 1,515.30 million for 2034 but provides 0 channel-level revenue observations; consequently, a largest-channel percentage cannot be calculated without introducing external estimates.

Likewise, no channel-specific CAGR is supplied for 2026–2034. Channel competition is expected to reflect the balance between prescription initiation through specialists and hospitals and repeat dispensing of oral therapies, including products designed for once-daily administration for periods extending to 24 months.

By End-User

End-users comprise hospitals and clinics, homecare settings, specialty centers, and others. No mandatory revenue allocation is available across these 4 categories, preventing defensible calculation of the largest or fastest-growing end-user segment despite the overall USD 567.86 million 2026 market and 13.09% forecast CAGR.

Treatment delivery increasingly spans specialist evaluation and home-based administration. A pivotal device study evaluating at-home stimulation targeted 120 participants, while a separate nutritional intervention trial remained recruiting in 2026, illustrating diversification beyond conventional facility-based treatment.

United States Endometriosis Treatment Market Counties Outlook

The geographic scope consists entirely of the United States, representing 100% of the supplied market geography and USD 567.86 million in 2026. No state, county, Census-region, or metropolitan revenue allocation was supplied; therefore, regional shares, county production figures, and subnational sector splits cannot be calculated reliably. National revenue reaches USD 1,515.30 million by 2034 at 13.09%, while the addressable disease population exceeds 6.5 million American women.

Top players in United States Endometriosis Treatment Market

• AbbVie Inc.
• Pfizer Inc.
• Sumitomo Pharma
• Bayer AG
• AstraZeneca
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.
• Organon & Co.
• Johnson & Johnson
• Sanofi
• Gedeon Richter Plc.
• Gesynta Pharma AB

Top Two Companies

• AbbVie Inc. Company-specific percentage revenue contribution is not supplied and therefore is not assigned an unsupported market share. AbbVie is positioned in endometriosis pharmacotherapy through its established reproductive-health portfolio and GnRH-based treatment presence. Against a 2026 addressable market of USD 567.86 million and an overall 13.09% CAGR, established prescription access, physician familiarity, and specialist-channel reach remain relevant competitive attributes.
• Pfizer Inc. A precise percentage share cannot be derived from the supplied mandatory tables. Pfizer's positioning is supported by MYFEMBREE, a once-daily therapy approved for moderate-to-severe endometriosis-associated pain for up to 24 months. The supporting SPIRIT program involved more than 1,200 women, with 75% dysmenorrhea response in treated groups and 59%–66% response for non-menstrual pelvic pain.

Recent Developments in United States Endometriosis Treatment Market

• 2026:The NOVA Phase 2 vipoglanstat study remained recruiting, targeting 190 patients and evaluating 2 doses, with completion estimated for June 2027.
• 2026:Main Line Health's randomized study of medical management following excisional endometriosis surgery remained recruiting, with its record updated June 12, 2026.
• 2026:A randomized nutritional intervention study sponsored by the University of California, San Diego remained recruiting following an April 28, 2026 update.
• 2026:The NettleEndo pivotal at-home stimulation study targeted approximately 120 participants, with study completion estimated for August 2026.
• 2025:A U.S. FDA-regulated MT-2990 endometriosis study record received an update posted December 31, 2025, reflecting continued clinical investigation of therapeutic alternatives.

Research Methodology

The analysis uses 2025 as the base year, 2026 as the current year, 2022–2024 as the historical period, and 2026–2034 as the forecast horizon. Mandatory supplied tables are the primary quantitative source: USD 502.30 million for 2025, USD 567.86 million for 2026, USD 1,515.30 million for 2034, and 13.09% CAGR. Segment percentages were calculated directly from supplied values, while epidemiology, clinical-development activity, and treatment evidence were cross-checked against U.S. government, ClinicalTrials.gov, and manufacturer sources. No unsupported county, company-share, production, surgery, channel, or end-user revenue estimates were introduced.